Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy.
Melissa BersanelliTeresa ZielliFabiana PerroneChiara CasartelliFabiana PratticòElena RapacchiRoberta CamisaMichele TognettoAlberto ClementeDiana GiannarelliSara Elena RebuzziAlessandro LeonettiPaola BordiMarcello TiseoSebastiano ButiPublished in: Immunotherapy (2020)
Aim: Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy. Patients & methods: We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective observational multicenter INVIDIa-2 study in the single center of Parma. Results: Among 53 patients, eight experienced influenza-like illness during the influenza season 2019/2020, and three of them had diagnosis of COVID-19. They were males, elderly, with cardiovascular disease. Radiological features of COVID-19 pneumonitis were found in all of three cases, although the pharyngeal swab resulted positive in only two. Two of these three patients died due to respiratory failure. Conclusion: Cancer patients are at high risk of severe events from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- respiratory failure
- papillary thyroid
- prognostic factors
- squamous cell carcinoma
- peritoneal dialysis
- type diabetes
- cross sectional
- clinical trial
- extracorporeal membrane oxygenation
- rheumatoid arthritis
- mechanical ventilation
- systemic sclerosis
- interstitial lung disease
- middle aged